Drug intelligence / Profile preview

NuP-4B dpi

Development stage: Preclinical
Lead developer: NuPeak Therapeutics
Modality: Small Molecules
Administration: Inhalation

Overview

NuP-4B dpi is an inhaled small molecule therapeutic candidate developed by NuPeak Therapeutics for the treatment of chronic respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD). The drug is delivered via a dry powder inhaler (DPI) and is designed to target biological pathways involved in airway inflammation and excessive mucus production. As of 2024, the program is in the IND-enabling stage of development, described by the sponsor as being in advanced development and finance-ready for IND approval and the initiation of clinical trials.

Targets

MAPK13 (p38δ MAPK)

Beyond the preview

Go deeper on NuP-4B dpi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuP-4B dpi.

Explore the full profile